sur Cheplapharm Arzneimittel GmbH (isin : DE000CHP2222)
CHEPLAPHARM Reports Stable Growth in the First Half of 2025
CHEPLAPHARM Arzneimittel GmbH, a key player in the pharmaceutical acquisition industry, reported a 12% increase in revenue to €813.4 million in the first half of 2025 compared to the latter part of 2024. EBITDA rose by 24% reaching €337.6 million, maintaining a strong margin of 42%.
After facing operational challenges in 2024, CHEPLAPHARM implemented a transformation program to stabilize its business. Co-CEO Sebastian Braun expressed satisfaction with the results, acknowledging improvements in process efficiency and operational stability.
The company successfully placed a €750 million bond, aiming to enhance financial flexibility and address medium-term maturities. CHEPLAPHARM continues to focus on acquiring established branded drugs, preparing for future market opportunities.
The workforce also expanded by 8%, reaching 789 employees. This growth occurs amid a competitive labor market, reinforcing CHEPLAPHARM's status as a leading employer.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Cheplapharm Arzneimittel GmbH